Recent Updates
Recently added Catalysts
INKT Positive Sentiment

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

Friday, July 28, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced their plans to release the second quarter 2023 financial results on August 10, 2023. CEO Jennifer Buell will also participate in the BTIG Virtual Biotechnology Conference on August 8, providing updates on the company's portfolio. This participation signals the company's efforts to maintain investor relations and boost visibility in the market.
Price reaction · baseline $16.7 (2023-07-27 close) · hit after-hours · clean, no other INKT news in the window
day 0 close · peak
+3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • MiNK Therapeutics is set to release its Q2 2023 financial results, indicating transparency and communication with investors.
  • Participation in the BTIG Virtual Biotechnology Conference showcases MiNK's commitment to engaging with the investment community.
  • CEO Jennifer Buell will discuss progress on their therapeutic portfolio, signaling confidence in ongoing projects.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+38%
120-day peak, hindsight
Typical move
6%
average across 2 past catalysts
Cash runway
~11 mo
Medium dilution risk

Full Press Release Details

Company announces participation in BTIG Virtual Biotechnology Conference
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its second quarter 2023 financial results via press release before the market opens on Thursday, Aug. 10.
In addition, MiNK Chief Executive Officer and President Jennifer Buell, Ph.D., will participate in and provide an update on the progress of the company’s portfolio at the following upcoming investor conference:
BTIG Virtual Biotechnology Conference 2023 – A fireside chat will be held virtually on Tuesday, Aug. 8, at 11:30 a.m. ET.
A replay of the fireside chat from the BTIG conference will be accessible on the company’s website at https://investor.minktherapeutics.com/events-and-presentations following the event.
About MiNK Therapeutics

Frequently Asked Questions

When will MiNK Therapeutics release its Q2 2023 financial results?

MiNK Therapeutics will release its second quarter 2023 financial results on August 10.

Who will represent MiNK at the BTIG Virtual Biotechnology Conference?

CEO Jennifer Buell, Ph.D., will represent MiNK at the conference.

What time is MiNK's fireside chat during the conference?

The fireside chat is scheduled for Tuesday, Aug. 8, at 11:30 a.m. ET.

Where can I access the replay of the BTIG conference chat?

The replay will be available on MiNK Therapeutics' website after the event.

What does MiNK Therapeutics specialize in?

MiNK Therapeutics specializes in allogeneic iNKT cell therapies for cancer treatment.

ShareAdd on Google
Tags: INKT MiNK Therapeutics biotechnology conference Q2 2023 results iNKT cell therapies
Last updated: Jul 28, 2023

Biotech snapshot

Cash runway
$9M liquidity · $1M/mo burn
~11 mo
Medium dilution risk

Catalyst track record

+38%
best trade around INKT's last catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for INKT.

See every catalyst's timing & PoA →